Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

138.88 USD -0.14 (-0.10%)
Official Closing Price Updated: 4:53 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 768,300
Open 139.59
Bid (Size) 135.53 (1)
Ask (Size) 152.00 (2)
Prev. Close 139.02
Today's Range 137.38 - 140.06
52wk Range 119.29 - 178.41
Shares Outstanding 117,002,019
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2021 on Thursday, April... 
From Business Wire News Releases
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim results from the ongoing Phase 1 study of ALN-AGT, a subcutaneous investigational... 
From Business Wire News Releases

Performance

YTD
+8.42%
+8.42%
1 Month
-4.32%
-4.32%
3 Month
-16.52%
-16.52%
6 Month
-4.48%
-4.48%
1 Year
+8.74%
+8.74%

More News

Read More
Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
From Business Wire News Releases
Alnylam Announces Publication of ILLUMINATE-A Phase 3 Study Results for Lumasiran in The New England Journal of Medicine
From Business Wire News Releases
Alnylam to Webcast Presentation at Stifel 3rd Annual CNS Day
From Business Wire News Releases
Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021
From Business Wire News Releases
Alnylam Issues Inaugural Corporate Responsibility Summary
From Business Wire News Releases
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
From Business Wire News Releases
Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
From Business Wire News Releases
Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront
Tags Biotech News DRNA
From Benzinga
Soleo Health to Administer Alnylam Pharmaceuticals’ GIVLAARI® (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.